Antibodies to mutated citrullinated vimentin and anti-cyclic citrullinated peptide antibodies in inflammatory bowel disease and related arthritis

被引:7
|
作者
Al-Jarallah, Khaled [1 ]
Shehab, Diaa [1 ]
Al-Attiyah, Rajaa [2 ]
Al-Azmi, Waleed [1 ]
Al-Fadli, Ahmad [3 ]
Haider, Mohammed Zafar [4 ]
Panaccione, Remo [5 ]
Ghosh, Subrata [5 ]
机构
[1] Kuwait Univ, Dept Med, Fac Med, Safat 13110, Kuwait
[2] Kuwait Univ, Dept Microbiol, Fac Med, Safat 13110, Kuwait
[3] Mubarak Al Kabeer Hosp, Dept Gastroenterol, Safat, Kuwait
[4] Kuwait Univ, Dept Pediat, Fac Med, Safat 13110, Kuwait
[5] Univ Calgary, Div Med, Fac Med, Calgary, AB T2N 1N4, Canada
关键词
arthritis; anti-cyclic citrullinated peptide antibodies; anti-mutated citrullinated vimentin; inflammatory bowel disease; spondylarthropathies; MUSCULOSKELETAL MANIFESTATIONS; RHEUMATOID-ARTHRITIS; CLASSIFICATION; EPIDEMIOLOGY; PREVALENCE; CCP;
D O I
10.1002/ibd.21937
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Antibodies that react with citrullinated proteins (anti-mutated citrullinated vimentin [anti-MCV] and second-generation anti-cyclic citrullinated peptide antibodies [anti-CCP2]) are markers for rheumatoid arthritis. Recent studies have demonstrated that these antibodies are present in other arthropathies including the spondyloarthritis, psoriatic arthritis, and juvenile idiopathic arthritis. Arthritis associated with inflammatory bowel disease (IBD) takes various forms, with some shared similarities with classic spondylarthropathies. Our objective was to investigate the role of anti-MCV and anti-CCP2 as potential biomarkers in IBD and related arthritis. Methods: In all, 125 IBD patients (71 males, 54 females) were compared to 81 age- and sex-matched healthy controls. Anti-MCV and Anti-CCP2 IgG were measured using an enzyme linked immunosorbent assay. Results: In the 125 IBD patients (mean age 32.6 +/- 12.3 years), 44 (35.2%) had ulcerative colitis and 81 (64.8%) had Crohn's disease. Forty-four (35.2%) IBD patients developed arthritic manifestations. Antibody positivity was observed in 24/125 (19.2%) IBD patients and in 18/81 (22.2%) healthy subjects. The proportion of anti-MCV positivity among IBD patients and healthy individuals were similar: 16.8% vs. 16.0%, P = 0.887. Anti-CCP2 positivity among IBD patients and healthy individuals was also comparable: 6.4% vs. 6.2%, P = 0.948. Similarly, the presence of anti-MCV and anti-CCP2 antibodies was not different among IBD patients with and without arthritis. The mean titers of antibodies were low: anti-MCV (29.6 +/- 7.5 U/mL) and anti-CCP2 (27.6 +/- 4.0 U/mL) in IBD patients with arthritis. Conclusions: Autoantibodies to citrullinated proteins were low in IBD-related arthritis. These findings suggest that these antibodies are not useful biomarkers in IBD to predict who may develop IBD-related arthropathy. (Inflamm Bowel Dis 2012)
引用
收藏
页码:1655 / 1662
页数:8
相关论文
共 50 条
  • [21] Anti-cyclic citrullinated peptide antibodies in elderly onset rheumatoid arthritis
    Riccieri, V.
    Macri, V.
    Germano, V.
    Vasile, M.
    Sciarra, I.
    Scrivo, R.
    Spadaro, A.
    Valesini, G.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 300 - 300
  • [22] Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis
    Rim Sghiri
    Elyes Bouagina
    Hela Zaglaoui
    Hajer Mestiri
    Latifa Harzallah
    Imed Harrabi
    Mehdi Ghannouchi
    Faycel Mokhtar
    Ibtissem Ghedira
    [J]. Rheumatology International, 2007, 27 : 1125 - 1130
  • [23] Anti-cyclic citrullinated peptide antibodies in psoriasis patients without arthritis
    Böckelmann, R
    Gollnick, H
    Bonnekoh, B
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (05): : 1701 - 1702
  • [24] Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis
    Sghiri, Rim
    Bouagina, Elyes
    Zaglaoui, Hela
    Mestiri, Hajer
    Harzallah, Latifa
    Harrabi, Imed
    Ghannouchi, Mehdi
    Mokhtar, Faycel
    Ghedira, Ibtissem
    [J]. RHEUMATOLOGY INTERNATIONAL, 2007, 27 (12) : 1125 - 1130
  • [25] Anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis
    Hromadnikova, I
    Stechova, K
    Vavrincova, P
    Hridelova, D
    Houbova, B
    Voslarova, S
    Nekvasilova, H
    Vavrinec, J
    [J]. AUTOIMMUNITY, 2002, 35 (06) : 397 - 401
  • [26] Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: An Italian multicentric study and review of the literature
    Bartoloni, Elena
    Alunno, Alessia
    Bistoni, Onelia
    Bizzaro, Nicola
    Migliorini, Paola
    Morozzi, Gabriella
    Doria, Andrea
    Mathieu, Alessandro
    Lotzniker, Milvia
    Allegri, Flavio
    Riccieri, Valeria
    Alpini, Claudia
    Gabrielli, Armando
    Tampoia, Marilina
    Gerli, Roberto
    [J]. AUTOIMMUNITY REVIEWS, 2012, 11 (11) : 815 - 820
  • [27] The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis
    Jansen, LMA
    van Schaardenburg, D
    van der Horst-Bruinsma, IE
    van de Stadt, RJ
    de Koning, MHMT
    Dijkmans, BAC
    [J]. JOURNAL OF RHEUMATOLOGY, 2003, 30 (08) : 1691 - 1695
  • [28] ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS
    Hamooda, Mohamed
    Fouad, Hala
    Galal, Nermeen
    Sewelam, Nadia
    Megahed, Dina
    [J]. RHEUMATOLOGY, 2017, 56
  • [29] Mutated citrullinated vimentin antibodies in rheumatoid arthritis
    Kuna, Andrea Tesija
    [J]. CLINICA CHIMICA ACTA, 2012, 413 (1-2) : 66 - 73
  • [30] EVALUATION OF CITRULLINATED ANTI-VIMENTIN ANTIBODIES, ANTI-CITRULLINATED CYCLIC PEPTIDE ANTIBODIES IN ECUADORIAN PATIENTS WITH RHEUMATOID ARTHRITIS
    Zurita-Salinas, Camilo
    Aguilera-Leon, Cristina
    Mestanza-Peralta, Marilu
    Zurita-Mestanza, Alejandro
    Meneses, Simon
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S55 - S55